

CERTIFICATE OF MAILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, DC 20231, on May 18, 1993 (Date of Deposit)

May 18, 1993

Date

Name

Henrietta Harrison



6-10-93

Boisner

1010/16104-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HOWARD WEINER

Serial No.: 07/460,852

Group Art Unit: ¹⁸¹³~~1815~~

Filed: February 21, 1990

Examiner: ~~A. Mohamed~~ *Kim 1851*

For: TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS *18x 6/29/93*

May 18, 1993

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

FEE TRANSMITTAL ACCOMPANYING THE PTO-1449 FORM

RECEIVED
JUN 11 1993
GROUP 1800

Sir:

Submitted herewith is a Form PTO-1449 and a copy of the reference listed thereon.

This Form is submitted later than three months after the filing date and after receipt of a first Office Action.

Enclosed is a check in the amount of \$200.00. The Commissioner is authorized to charge any additional fee or to credit any overpayment to Deposit Account No. 04-0100.

Respectfully submitted,

Adda C. Gogoris

Adda C. Gogoris
Reg. No. 29,714
Attorney for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, New York 10022
(212) 527-7700

100 MG 06/09/93 07460852

1 126 200.00 CK

CERTIFICATE OF MAILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, DC 20231, on May 18, 1993 (Date of Deposit)

May 18, 1993

Date

Name

Henrietta Maaron



18K
6/29/93
091
Kim, K

#23

1010/16104-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HOWARD WEINER

Serial No.: 07/460,852

Group Art Unit: 1815

Filed: February 21, 1990

Examiner: A. Mohamed

For: TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS

May 18, 1993

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RECEIVED
JUN 11 1993
GROUP 1800

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the disclosure duty under 37 CFR §§ 1.56 and 1.97, copies of the documents listed on the accompanying PTO-1449 form are enclosed.¹ These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

¹ If a listed document is not in the English language and an English translation is readily available, such translation is also enclosed and attached to the copy of the document. If a translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then the English equivalent patent is also listed on the enclosed form along with the corresponding foreign language patent and a connecting arrow indicates the relationship between them. If no such English language equivalent is cited, then none is known to the undersigned.

In accordance with MPEP Sections 609 and 707.05(b) it is requested that each document cited (including any cited in applicants' specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with.

The present Disclosure Statement is also being submitted in compliance with 37 CFR § 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR §§ 1.104(a) and 1.106(b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,



Adda C. Gogoris
Reg. No. 29,714
Attorney for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, New York 10022
(212) 527-7700